AKT1 and cancer: The distinct cancer types in Mito-Ob and mMito-Ob mice imply that PHB Y114F mutation may have activated an immune dysregulation mediated by enhanced PI3K-Akt signaling in monocytic cells, which increased the likelihood of immune-base complications such as the observed lymph node tumor and autoimmune diabetes [155].